Furosemide Micronized Formulation for Consistent Diuresis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current furosemide formulations exhibit a narrow absorption window, leading to rapid and inconsistent diuresis, renal stress, and decreased efficacy over time, necessitating increased dosing and potentially causing kidney issues and high blood pressure in patients with congestive heart failure.

Innovation Solution

A pharmaceutical composition comprising a micronized hydrophobic agent, such as furosemide, combined with a phase-inverted form and a pH-altering polymer like Eudragit, formulated into particles of at least 1 micrometer in size to improve bioavailability and regulate diuresis, reducing the initial diuretic spike and maintaining consistent urine output.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Speed

If immediate release oral formulations of furosemide are used, then rapid onset of diuresis is achieved, but inconsistent fluid loss and renal stress occur

Engineering Contradiction:

Improveonset of diuresisVSAvoidconsistency of fluid loss

Core Design Contradiction:

SpeedVSReliability

Solution Approach 1:

The patent segments the single-dose bolus administration into multiple smaller doses administered at different rates. The composition includes furosemide in a controlled-release formulation that divides the delivery of the diuretic agent over time, preventing the sudden spike associated with immediate release formulations while maintaining consistent diuretic effect throughout the day.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent implements a dynamic dosing strategy where the rate of furosemide administration is adjusted over time. The composition is designed to release the diuretic agent at a controlled, gradually decreasing rate, transforming the static bolus injection into a dynamic, time-varying delivery system that mimics physiological diuresis patterns.

Inventive Principle:

Principle #15Dynamics

2Productivity

If continuous administration at lower concentrations is used, then diuretic efficiency is improved, but formulation complexity increases

Engineering Contradiction:

Improvediuretic efficiencyVSAvoidformulation complexity

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

The patent changes the physical and chemical parameters of the furosemide formulation to achieve controlled release. Specifically, it uses a hydrophilic matrix forming gel structure that controls the diffusion rate of furosemide, transforming the drug's release characteristics from immediate to sustained without requiring complex delivery devices or multiple administration steps.

Inventive Principle:

Principle #35Parameter changes

3Duration of action of moving object

If dose escalation is implemented to maintain efficacy, then diuretic effect is sustained, but renal stress and adverse effects increase

Engineering Contradiction:

Improveduration of diuretic effectVSAvoidrenal stress

Core Design Contradiction:

Duration of action of moving objectVSObject-affected harmful factors

Solution Approach 1:

The patent ensures continuous diuretic action through a sustained-release formulation that maintains therapeutic furosemide levels throughout the day. The hydrophilic matrix continuously releases the drug at a controlled rate, eliminating the need for dose escalation and preventing the intermittent high-dose peaks that cause renal stress and adverse effects.

Inventive Principle:

Principle #20Continuity of useful action

4Reliability

If micronized particles of at least 1 micrometer are used, then bioavailability is improved, but manufacturing precision requirements increase

Engineering Contradiction:

ImprovebioavailabilityVSAvoidparticle size control

Core Design Contradiction:

ReliabilityVSManufacturing precision

Solution Approach 1:

The patent creates a composite material system combining furosemide with a hydrophilic matrix former that forms a gel structure. This composite approach allows the use of micronized particles (≥1 μm) for improved bioavailability while the matrix structure provides a forgiving manufacturing environment that tolerates broader particle size distributions without compromising performance.

Inventive Principle:

Principle #40Composite materials

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The micronized formulation achieves a more linear and sustained diuretic effect, reducing renal stress and the need for frequent dosing, while maintaining cumulative urine output over 10 hours, thereby improving patient comfort and reducing adverse effects.

Implementation Method 1

formulating a mixture of a hydrophobic agent, such as furosemide, and a phase inverted micronized form of the agent with an acceptable salt or buffer

Methodology Applied

Scientific EffectpH alteration:

Implementation Method 2

a micronized phase inverted form of the agent with an acceptable salt or buffer, wherein the composition has an average particle size of at least about 1 micrometer

Methodology Applied

Scientific EffectPhase inversion:

Data Source

PatentUS8685947B2Compositions and methods for loop diuretics with consistent bioavailability

Publication Date: 2014.04.01 BROWN UNIVERSITY

AI summary

Diuretic bioactivity profiles of phase inversion micronized furosemide and furosemide co-precipitated with Eudragit L100, and mixtures of those formulations with stock furosemide, reduced or eliminated the rapid spike in diuresis associated with immediate release formulations and maintained cumulative urine output. Of the formulations tested, each of a mixture of micronized furosemide with stock furosemide, and Eudragit L100 polymer with stock furosemide demonstrated optimal diuretic bioactivity profiles in subjects.